The average sales price (ASP) decrease proposed by our friends at Medicare could change the face of private practice infusion suites nationwide. This would be bad for patient care; almost as importantly, this decrease would be very bad for the rheumatology business.
The implementation date of the International Classification of Diseases, Clinical Modification, has come and gone, and we have survived what is arguably the most significant change for providers in the history of reporting healthcare services. As the dust settles, an assessment is recommended.
Medicare is poised to incorporate new quality metrics as a guide for payments. At ASH 2015, the CSO of the National Quality Forum discussed the need for measures and reporting systems that reflect patient care and care coordination.
In a recent announcement, the National Organization of Rheumatology Managers (NORM) has released what they call the “Stop CMS Advocacy Toolkit,” cautioning rheumatology practice managers that drug payments from Medicare are at risk, and urging them to get involved.
- CMS Strengthens Medicare Advantage and Part D
- New Affordable Care Act Initiative Launched
- CMS to Add 5500 ICD-10 Codes
- New Interactive Tool Seeks to Raise Awareness About Health Disparities
You pay more than your fair share of taxes, so when it comes to your investments, why would you pay more than you absolutely have to? While it may be too late to save taxes on investments you made last year, it’s the perfect time to focus on saving money this year, so we want to share some tax tactics to keep your tax bill for 2016 in check.
Healthcare delivery is changing drastically. Demographics, technology, economics, societal forces, and many other factors are prompting the industry’s transformation as we begin 2016 and beyond. Although change is always a bit jarring, sometimes it actually makes sense. Here are 8 emerging trends that are changing healthcare for the better.
The following clinical trials represent a selection of key clinical trials that are currently recruiting patients with ankylosis for inclusion in investigations of new therapies and new regimens of available therapies for patients with ankylosing rheumatic diseases. Each clinical trial description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. The information below can help oncology practice managers and providers direct their eligible patients to one of these clinical trials.
Results 1 - 8 of 8